New "Buy" Rating Can't Boost WWE Stock

WWE options traders have been bullish, too

by Karee Venema

Published on Aug 14, 2019 at 10:10 AM

Rosenblatt Securities initiated coverage on World Wrestling Entertainment, Inc. (NASDAQ:WWE) with a "buy" rating and an $85 price target -- a 27.4% premium to last night's close. The brokerage firm said the entertainment name is an attractive target for those looking to trade the "content is king" theme, and sees a compelling entry point following WWE stock's recent pullback.

Looking closer, the shares have shed 34% since topping out at a record high of $100.45 in late April. And since a late-July rejection in the $78-$76 region -- a ceiling in recent months -- WWE stock is down 16%. Today, the equity is off 0.8% at $66.16 amid stiff broad-market headwinds.

Despite these technical troubles, analysts remain enamored with World Wrestling Entertainment. In fact, Rosenblatt joined seven other brokerage firms with its "buy" rating, compared to just one "hold" recommendation, and not a single "sell." Meanwhile, the average 12-month price target sits all the way up at $97.50.

 This bullish bias is seen in the options pits, too. The October 75 call and 60 put are home to peak WWE open interest, and it looks like one speculator used the options to initiate a synthetic long strategy in late July when the shares were trading near $68.50.

Shorter-term traders have targeted the August 80 call, and data from Trade-Alert points to buy-to-open activity here. If this is the case, the call buyers' goal is for WWE stock to break out above $80 by expiration at the close this Friday, Aug. 16.


a schaeffer's exclusive

PLAY TRENDS LIKE A PRO!

5 tips to leverage profits in this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.
Wall Street Reacts to Fed Decision, Trade Deal
Investors waited and reacted to the Fed decision and trade headlines
Sarepta Therapeutics Stock Eyes Best Day in 3 Years on FDA Reversal
SRPT is buzzing on the FDA's change of heart
The Trend Minting Millionaires -- But Who Is Really Paying?
Porter Stansberry is making a concerning prediction.